Literature DB >> 24326388

Immune cell infiltration in malignant middle cerebral artery infarction: comparison with transient cerebral ischemia.

Hannah X Chu1, Hyun Ah Kim1, Seyoung Lee1, Jeffrey P Moore1, Christopher T Chan1, Antony Vinh1, Mathias Gelderblom2, Thiruma V Arumugam3, Brad R S Broughton1, Grant R Drummond1, Christopher G Sobey1.   

Abstract

We tested whether significant leukocyte infiltration occurs in a mouse model of permanent cerebral ischemia. C57BL6/J male mice underwent either permanent (3 or 24 hours) or transient (1 or 2 hours+22- to 23-hour reperfusion) middle cerebral artery occlusion (MCAO). Using flow cytometry, we observed ∼15,000 leukocytes (CD45(+high) cells) in the ischemic hemisphere as early as 3 hours after permanent MCAO (pMCAO), comprising ∼40% lymphoid cells and ∼60% myeloid cells. Neutrophils were the predominant cell type entering the brain, and were increased to ∼5,000 as early as 3 hours after pMCAO. Several cell types (monocytes, macrophages, B lymphocytes, CD8(+) T lymphocytes, and natural killer cells) were also increased at 3 hours to levels sustained for 24 hours, whereas others (CD4(+) T cells, natural killer T cells, and dendritic cells) were unchanged at 3 hours, but were increased by 24 hours after pMCAO. Immunohistochemical analysis revealed that leukocytes typically had entered and widely dispersed throughout the parenchyma of the infarct within 3 hours. Moreover, compared with pMCAO, there were ∼50% fewer infiltrating leukocytes at 24 hours after transient MCAO (tMCAO), independent of infarct size. Microglial cell numbers were bilaterally increased in both models. These findings indicate that a profound infiltration of inflammatory cells occurs in the brain early after focal ischemia, especially without reperfusion.

Entities:  

Mesh:

Year:  2013        PMID: 24326388      PMCID: PMC3948121          DOI: 10.1038/jcbfm.2013.217

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  40 in total

1.  Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke.

Authors:  Arthur Liesz; Wei Zhou; Éva Mracskó; Simone Karcher; Henrike Bauer; Sönke Schwarting; Li Sun; Dunja Bruder; Sabine Stegemann; Adelheid Cerwenka; Clemens Sommer; Alexander H Dalpke; Roland Veltkamp
Journal:  Brain       Date:  2011-03       Impact factor: 13.501

Review 2.  Dendritic cells and tolerance induction.

Authors:  R J Steptoe; A W Thomson
Journal:  Clin Exp Immunol       Date:  1996-09       Impact factor: 4.330

3.  Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome.

Authors:  Vanessa H Brait; Jennifer Rivera; Brad R S Broughton; Seyoung Lee; Grant R Drummond; Christopher G Sobey
Journal:  Brain Res       Date:  2010-12-04       Impact factor: 3.252

Review 4.  The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct?

Authors:  Dwaine F Emerich; Reginald L Dean; Raymond T Bartus
Journal:  Exp Neurol       Date:  2002-01       Impact factor: 5.330

Review 5.  Functional outcomes of decompressive hemicraniectomy following malignant middle cerebral artery infarctions: a systematic review.

Authors:  Alison McKenna; Colin F Wilson; Sheena B Caldwell; David Curran
Journal:  Br J Neurosurg       Date:  2012-02-09       Impact factor: 1.596

6.  Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke.

Authors:  F C Barone; L M Hillegass; M N Tzimas; D B Schmidt; J J Foley; R F White; W J Price; G Z Feuerstein; R K Clark; D E Griswold
Journal:  Mol Chem Neuropathol       Date:  1995-01

Review 7.  Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.

Authors:  Carol Kilkenny; William J Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  PLoS Biol       Date:  2010-06-29       Impact factor: 8.029

8.  Neutrophil elastase and neurovascular injury following focal stroke and reperfusion.

Authors:  Ann M Stowe; Tracy L Adair-Kirk; Ernesto R Gonzales; Ronald S Perez; Aarti R Shah; Tae S Park; Jeffrey M Gidday
Journal:  Neurobiol Dis       Date:  2009-04-22       Impact factor: 5.996

9.  Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study.

Authors:  C J S Price; D K Menon; A M Peters; J R Ballinger; R W Barber; K K Balan; A Lynch; J H Xuereb; T Fryer; J V Guadagno; E A Warburton
Journal:  Stroke       Date:  2004-05-20       Impact factor: 7.914

10.  Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial.

Authors:  Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke
Journal:  Stroke       Date:  2007-08-09       Impact factor: 7.914

View more
  83 in total

Review 1.  Glia-immune interactions post-ischemic stroke and potential therapies.

Authors:  Jessica Hersh; Shao-Hua Yang
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-11

2.  Experimental ischemic stroke induces long-term T cell activation in the brain.

Authors:  Luokun Xie; Wenjun Li; Jessica Hersh; Ran Liu; Shao-Hua Yang
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-10       Impact factor: 6.200

3.  IL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke.

Authors:  Shenpeng R Zhang; Marius Piepke; Hannah X Chu; Brad Rs Broughton; Raymond Shim; Connie Hy Wong; Seyoung Lee; Megan A Evans; Antony Vinh; Samy Sakkal; Thiruma V Arumugam; Tim Magnus; Samuel Huber; Mathias Gelderblom; Grant R Drummond; Christopher G Sobey; Hyun Ah Kim
Journal:  JCI Insight       Date:  2018-09-20

Review 4.  Role of CCR2 in inflammatory conditions of the central nervous system.

Authors:  Hannah X Chu; Thiruma V Arumugam; Mathias Gelderblom; Tim Magnus; Grant R Drummond; Christopher G Sobey
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-02       Impact factor: 6.200

5.  Identification of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P1) as a Pathogenic Factor in Transient Focal Cerebral Ischemia.

Authors:  Bhakta Prasad Gaire; Chi-Ho Lee; Arjun Sapkota; Sang Yeul Lee; Jerold Chun; Hee Jun Cho; Tae-Gyu Nam; Ji Woong Choi
Journal:  Mol Neurobiol       Date:  2017-03-25       Impact factor: 5.590

Review 6.  Clinical Trials of Immunomodulation in Ischemic Stroke.

Authors:  Roland Veltkamp; Dipender Gill
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 7.  Brain-immune interactions in perinatal hypoxic-ischemic brain injury.

Authors:  Bo Li; Katherine Concepcion; Xianmei Meng; Lubo Zhang
Journal:  Prog Neurobiol       Date:  2017-10-27       Impact factor: 11.685

Review 8.  Long-term T cell responses in the brain after an ischemic stroke.

Authors:  Uma Maheswari Selvaraj; Ann M Stowe
Journal:  Discov Med       Date:  2017-12       Impact factor: 2.970

Review 9.  Inflammatory Disequilibrium in Stroke.

Authors:  Danica Petrovic-Djergovic; Sascha N Goonewardena; David J Pinsky
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

10.  The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration.

Authors:  Thorsten R Doeppner; Jens R Pehlke; Britta Kaltwasser; Jana Schlechter; Ertugrul Kilic; Mathias Bähr; Dirk M Hermann
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-29       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.